Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Targeted Oncology

Volumn 10, Issue 1, 2015, Pages 45-53

  Rini, Brian I ^a   Quinn, David I ^b   Baum, Michael ^c   Wood, Laura S ^a   Tarazi, Jamal ^d   Rosbrook, Brad ^d   Arruda, Lillian Shahied ^d   Cisar, Laura ^e   Roberts, W Gregory ^d   Kim, Sinil ^d   Motzer, Robert J ^c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PFIZER INC   (United States)

^e Pfizer Ltd   (United States)

Author keywords

Axitinib; Blood pressure; Hypertension; Renal cell carcinoma; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; NICOTINAMIDE; SORAFENIB;

ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84894625038     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0307-z     Document Type: Article

References (33)

1. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272–7283
2. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939
3. Cohen RB, Oudard S (2012) Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 30:2066–2079
4. Bhargava P (2009) VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297:R1–R5
5. Jain M, Townsend RR (2007) Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 9:320–328
6. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD (2010) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30:591–601
7. Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20:81–82
8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
11. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068
12. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD (2010) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56:1131–1136
13. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54:652–658
14. Hayman SR, Leung N, Grande JP, Garovic VD (2012) VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 14:285–294
15. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35–52
16. Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19:927–934
17. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de Koning E (2008) Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14:3470–3476
18. Keenan NL, Rosendorf KA (2011) Prevalence of hypertension and controlled hypertension—United States, 2005–2008. MMWR Surveill Summ 60(Suppl):94–97
19. Miller DC, Ruterbusch J, Colt JS, Davis FG, Linehan WM, Chow WH, Schwartz K (2010) Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case–control study. J Urol 184:2254–2258
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
21. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552–562
22. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006). National Cancer Institute Division of Cancer Treatment and Diagnosis. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 10 January 2013
23. INLYTA® (axitinib) prescribing information (2012). Pfizer Inc. http://labeling.pfizer.com/ShowLabeling.aspx?id=759. Accessed 10 January 2013
24. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984
25. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ (2009) Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 15:6250–6257
26. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (2010). National Cancer Institute DIvision of Cancer Treatment and Diagnosis. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 10 January 2013
27. US Department of Health and Human Services (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf. Accessed 10 January 2013
28. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117–123
29. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084–1096
30. Bellmunt J, Eisen T, Fishman M, Quinn D (2011) Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 78:24–32
31. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D (2008) Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52:10–29
32. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596–604
33. Kirkali Z (2011) Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int 107:1722–1732